Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as REGN15160 (IV)
REGN15160 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Lower IV Dose | EXPERIMENTAL | Randomized 3:1 |
| Mid IV Dose 1 | EXPERIMENTAL | Randomized 3:1 |
| Mid IV Dose 2 | EXPERIMENTAL | Randomized 3:1 |
| Higher IV Dose | EXPERIMENTAL | Randomized 3:1 |
| Lower SC Dose | EXPERIMENTAL | Randomized 3:1 |
| Mid SC Dose | EXPERIMENTAL | Randomized 3:1 |
| Higher SC Dose | EXPERIMENTAL | Randomized 3:1 |
| Name | Type | Description |
|---|---|---|
| REGN15160 (IV) | DRUG | Administered in single intravenous (IV) dose |
| Matching Placebo (IV) | DRUG | Administered in single IV dose |
| REGN15160 (SC) | DRUG | Administered in single subcutaneous (SC) dose |
| Matching Placebo (SC) | DRUG | Administered in single SC dose |
Key Inclusion Criteria: 1. Has a SARS-CoV-2 negative test result from a sample collected ≤72 hours prior to randomization using a local reverse transcription polymerase chain reaction (RT-PCR) test or other molecular diagnostic assay and sample collection following assay standards 2. Has received c...
REGN15160 is an investigational small molecule developed by Regeneron Pharmaceuticals, Inc. It has been studied in a Phase 1 clinical trial in adult healthy volunteers. The specific disease indication for REGN15160 has not been publicly disclosed.
REGN15160 is being developed by Regeneron Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker REGN. Regeneron sponsored the Phase 1 trial of REGN15160 conducted in Belgium.
REGN15160 is in Phase 1 development. One Phase 1 trial of REGN15160 has been completed, and no active trials are currently listed. The study enrolled 104 participants and was randomized, double-blind, and controlled.
REGN15160 has been evaluated in one completed Phase 1 trial, NCT05293678, titled Safety and Tolerability of Regeneron Anti-SARS-CoV-2 Monoclonal Antibody/Ies in Adult Healthy Volunteers as Related to COVID-19. The trial enrolled 104 healthy adult volunteers aged 18 years and older in Belgium.
Yes, REGN15160 (IV) refers to the same investigational asset as REGN15160. The parenthetical IV designation distinguishes the intravenous formulation. Both names refer to the small molecule developed by Regeneron Pharmaceuticals, Inc. that was studied in the completed Phase 1 trial NCT05293678.